Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

The survey of 1,078 adults, carried out by Ipsos, found 24% of people would use weight-loss jabs if they were provided for ...

Today it is happening again with GLP1 agonists like Semaglutide with the brand names of Wegovy, Ozempic, and Rybelsus and similar drugs like ... term side effects as this is a new trend among ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

However, while Wegovy is prescribed by the NHS for weight management, Rybelsus is not licensed for such and is only available as a treatment for Type 2 diabetes. There are other limitations too. In ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

Novo Nordisk reported one counterfeit pen contained the diabetes medicine insulin ... Novo Nordisk, the maker of Ozempic, Rybelsus and Wegovy, said in a statement to CBS News: "It's important that ...

So what is semaglutide and who uses it in India? Semaglutide belongs to the class of drugs called Glucagon-like peptide-1 ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...